CEA、CYFRA21-1联合影像学对肺癌患者预后判断的临床研究

Clinical trial of CEA and CYFRA21-1 combined with imaging on prognosis of lung cancer patients

目的观察肺癌患者外周血生物标志物血清癌胚抗原(CEA)和细胞角蛋白19片段(CYFRA21-1)表达情况,并探讨2种标志物联合影像学指标对肺癌患者预后的判断价值。方法回顾性分析肺癌患者临床资料,所有患者均接受化疗后随访半年,观察患者预后结局,将癌细胞复发、转移或病死的患者纳入预后不良组,其余患者纳入预后良好组。比较化疗前2组患者的基线资料、实验室资料、多层螺旋电子计算机断层扫描(MSCT)检查结果,分析外周血生物标志物CEA、CYFRA21-1联合MSCT检查在预测肺癌患者预后的应用情况。结果完成化疗后随访的102例肺癌患者中16例复发、10例转移、5例死亡,预后不良占30.39%(31例/102例)。预后不良组和预后良好组的CEA表达水平分别为(28.03±8.49)和(17.03±5.78)ng·mL^(-1),CYFRA21-1表达水平分别为(7.03±1.46)和(4.86±0.94)ng·mL^(-1),CA125表达水平分别为(86.16±9.42)和(72.33±7.83)ng·mL^(-1),血流量分别为(94.58±15.63)和(78.21±10.23)mL·s^(-1),表面渗透性分别为(18.44±3.67)和(15.61±3.38)mL·min^(-1)·100 g^(-1),到达峰值时间分别为(26.58±5.50)和(20.15±3.49)s,肿瘤体积分别为(88.54±12.22)和(77.19±10.56)mm3,两组间比较,在统计学上差异均有统计学意义(均P<0.05)。受试者工作特征(ROC)曲线图显示CEA和CYFRA21-1的血浆浓度时间曲线下面积(AUC)分别为0.854和0.892,血流量、表面渗透性、到达峰值时间、肿瘤体积的AUC分别为0.810、0.719、0.834、0.744,联合检测的AUC为0.954。结论外周血生物标志物CEA、CYFRA21-1水平在肺癌患者血清中呈高表达,且CEA、CYFRA21-1联合影像学指标有助于预测肺癌患者的预后。

Objective To observethe expression of serum carcinoembryonic antigen(CEA)and cytokeratin 199fragment(CYFRA21-1)in peripheral blood of lung cancer patients,and to explore the prognostic value of combined imaging indicators for lung cancer patients.Methods Retrospectively analyze clinical data of lung cancer patients;all patients were followed up for six months after chemotherapy;observed the prognosis outcome of patients;included patients with cancer cell recurrence,metastasis or death in the poor prognosis group,and the rest of the patients in the good prognosis group.The baseline data,laboratory data and multi-slice spiral computed tomography(MSCT)results of the two groups before chemotherapy were compared;the application of peripheral blood biomarkers CEA and CYFRA21-1 combined with MSCT in predicting the prognosis of patients with lung cancer was analyzed.Results Among the 102 lung cancer patients who completed chemotherapy follow-up,16 had recurrence,10 had metastasis,and 5 died,accounting for 30.39%(31 cases/102 cases)of poor prognosis;the levels of CEA expression in the poor prognosis group and the good prognosis group were(28.03±8.49)and(17.03±5.78)ng·mL^(-1),respectively;the levels of CYFRA21-1 expression were(7.03±1.46)and(4.86±0.94)ng·mL^(-1),respectively;the levels of CA125 expression were(86.16±9.42)and(72.33±7.83)ng·mL^(-1),respectively;blood flow rates were(94.58±15.63)and(78.21±10.23)mL·s^(-1),respectively;surface permeability were(18.44±3.67)and(15.61±3.38)mL·min^(-1)·100g^(-1),respectively;time to peak were(26.58±5.50)and(20.15±3.49)s,respectively;tumor volume were(88.54±12.22)and(77.19±10.56)mm^(-1),respectively;the differences between the two groups were statistically significant(all P<0.05).The receiver operating characteristic(ROC)curve showed that the areas under the curves(AUC)of CEA and CYFRA21-1 plasma concentrations were 0.854 and 0.892;the AUC of blood flow rate,surface permeability,time to peak,and tumor volume were 0.810,0.719,0.834,and 0.744,respectively;and the AUC of the combined test was 0.954.Conclusion The levels of peripheral blood biomarkers CEA and CYFRA21-1 are highly expressed in the serum of lung cancer patients and the combination of CEA,CYFRA21-1 with imaging indicators is helpful in predicting the prognosis of lung cancer patients.